Top

Published in:

Open Access 17-07-2023 | Long-COVID Syndrome | Review

Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID

Authors: Tamás Constantin, Tamás Pék, Zsuzsanna Horváth, Diána Garan, Attila J. Szabó

Published in: Inflammopharmacology | Issue 5/2023

Abstract

The COVID-19 pandemic caused by the coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) has significantly affected people around the world, leading to substantial morbidity and mortality. Although the pandemic has affected people of all ages, there is increasing evidence that children are less susceptible to SARS-CoV-2 infection and are more likely to experience milder symptoms than adults. However, children with COVID-19 can still develop serious complications, such as multisystem inflammatory syndrome in children (MIS-C). This narrative review of the literature provides an overview of the epidemiology and immune pathology of SARS-CoV-2 infection and MIS-C in children. The review also examines the genetics of COVID-19 and MIS-C in children, including the genetic factors that can influence the susceptibility and severity of the diseases and their implications for personalized medicine and vaccination strategies. By examining current evidence and insights from the literature, this review aims to contribute to the development of effective prevention and treatment strategies for COVID-19, MIS-C, and long COVID syndromes in children.

Akbil B, Meyer T, Stubbemann P et al (2021) Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm. Medrxiv. https://doi.org/10.1101/2021.11.12.21266249CrossRef

Akindele NP, Pieterse L, Suwanmanee S, Griffin DE (2022) B cell responses in hospitalized SARS-CoV-2-infected children with and without multisystem inflammatory syndrome. J Infect Dis. https://doi.org/10.1093/infdis/jiac119CrossRef

Arostegui D, Castro K, Schwarz S et al (2021) Persistent SARS-CoV-2 nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3 months after acute infection. Jpgn Reports 3:e152. https://doi.org/10.1097/pg9.0000000000000152CrossRefPubMedPubMedCentral

Asano T, Boisson B, Onodi F et al (2021) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 6:eabl4348. https://doi.org/10.1126/sciimmunol.abl4348CrossRefPubMedPubMedCentral

Bami S, Vagrecha A, Soberman D et al (2020) The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 67:e28581. https://doi.org/10.1002/pbc.28581CrossRefPubMed

Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eabd4585. https://doi.org/10.1126/science.abd4585CrossRefPubMedPubMedCentral

Bastard P, Gervais A, Voyer TL et al (2021) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6:eabl4340. https://doi.org/10.1126/sciimmunol.abl4340CrossRefPubMedPubMedCentral

Bastard P, Vazquez S, Liu J et al (2022) Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol. https://doi.org/10.1126/sciimmunol.abp8966CrossRefPubMedPubMedCentral

Beccuti G, Ghizzoni L, Cambria V et al (2020) A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor. J Endocrinol Invest 43:1175–1177. https://doi.org/10.1007/s40618-020-01323-4CrossRefPubMedPubMedCentral

Beck A, Gandhi M (2021) Adjudicating reasons for hospitalization reveals that severe illness from COVID-19 in children is rare. Hosp Pediatrics 11:e159–e160. https://doi.org/10.1542/hpeds.2021-006084CrossRef

Beckmann ND, Comella PH, Cheng E et al (2021) Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat Commun 12:4854. https://doi.org/10.1038/s41467-021-24981-1CrossRefPubMedPubMedCentral

Berg SK, Nielsen SD, Nygaard U et al (2022) Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 6:240–248. https://doi.org/10.1016/s2352-4642(22)00004-9CrossRef

Bhopal SS, Bagaria J, Olabi B, Bhopal R (2021) Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Heal 5:e12–e13. https://doi.org/10.1016/s2352-4642(21)00066-3CrossRef

Borch L, Holm M, Knudsen M et al (2022a) Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur J Pediatr 181:1597–1607CrossRefPubMedPubMedCentral

Buszko M, Nita-Lazar A, Park J-H et al (2021) Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol 22:404–411. https://doi.org/10.1038/s41590-021-00901-9CrossRefPubMedPubMedCentral

Chen M-R, Kuo H-C, Lee Y-J et al (2021) Phenotype, susceptibility, autoimmunity, and immunotherapy between kawasaki disease and coronavirus disease-19 associated multisystem inflammatory syndrome in children. Front Immunol 12:632890. https://doi.org/10.3389/fimmu.2021.632890CrossRefPubMedPubMedCentral

Cheng MH, Zhang S, Porritt RA et al (2020) Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci 117:25254–25262. https://doi.org/10.1073/pnas.2010722117CrossRefPubMedPubMedCentral

Choi JH, Choi S-H, Yun KW (2022) Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. https://doi.org/10.3346/jkms.2022.37.e35CrossRefPubMedPubMedCentral

Cohen JM, Carter MJ, Cheung CR et al (2022) Lower risk of multisystem inflammatory syndrome in children (MIS-C) with the Delta and Omicron variants of SARS-CoV-2. Clin Infect Dis Official Publ Infect Dis Soc Am 76:ciac553

Cole LD, Slate M, Minneman S, Bozzella MJ (2022) Early release—multisystem inflammatory syndrome after breakthrough SARS-CoV-2 infection in 2 immunized adolescents, united states—volume 28, Number 7—July 2022—emerging infectious diseases Journal—CDC. Emerg Infect Dis 28:1456–1459. https://doi.org/10.3201/eid2807.220560CrossRefPubMedPubMedCentral

Consiglio CR, Cotugno N, Sardh F et al (2020) The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183:968-981.e7. https://doi.org/10.1016/j.cell.2020.09.016CrossRefPubMedPubMedCentral

Cron RQ (2022) Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children. Curr Opin Rheumatol 34:274–279. https://doi.org/10.1097/bor.0000000000000889CrossRefPubMed

Diao B, Wang C, Tan Y et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11:827. https://doi.org/10.3389/fimmu.2020.00827CrossRefPubMedPubMedCentral

Ding J, Hostallero DE, Khili MRE et al (2021) A network-informed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes’ interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-19. Plos Comput Biol 17:e1008810. https://doi.org/10.1371/journal.pcbi.1008810CrossRefPubMedPubMedCentral

Du W, Yu J, Liu X et al (2020) Persistence of SARS-CoV-2 virus RNA in feces: a case series of children. J Infect Public Heal 13:926–931. https://doi.org/10.1016/j.jiph.2020.05.025CrossRef

Eloseily EM, Weiser P, Crayne CB et al (2020) Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 72:326–334. https://doi.org/10.1002/art.41103CrossRefPubMed

Fage C, Hénaut M, Carbonneau J et al (2022) Influenza A(H1N1)pdm09 virus but not respiratory syncytial virus interferes with SARS-CoV-2 replication during sequential infections in human nasal epithelial cells. Viruses 14:395. https://doi.org/10.3390/v14020395CrossRefPubMedPubMedCentral

Feldstein LR, Rose EB, Horwitz SM et al (2020) Multisystem inflammatory syndrome in U.S. children and adolescents. New Engl J Med 383:334–346. https://doi.org/10.1056/nejmoa2021680CrossRefPubMed

Forrest CB, Burrows EK, Mejias A et al (2022) Severity of acute COVID-19 in children 18 years old march 2020 to December 2021. Pediatrics. https://doi.org/10.1542/peds.2021-055765CrossRefPubMed

Gao P, Kang L-Y, Liu J, Liu M (2023) Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis. World J Pediatr. https://doi.org/10.1007/s12519-022-00680-9CrossRefPubMedPubMedCentral

Ghosh P, Katkar GD, Shimizu C et al (2022) An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease. Nat Commun 13:2687. https://doi.org/10.1038/s41467-022-30357-wCrossRefPubMedPubMedCentral

Gruber CN, Patel RS, Trachtman R et al (2020) mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 183:982-995.e14. https://doi.org/10.1016/j.cell.2020.09.034CrossRefPubMedPubMedCentral

Han MS, Choi EH, Chang SH et al (2021) Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea. Jama Pediatr 175:73–80. https://doi.org/10.1001/jamapediatrics.2020.3988CrossRefPubMed

Hasan A, Al-Ozairi E, Al-Baqsumi Z et al (2021) Cellular and humoral immune responses in covid-19 and immunotherapeutic approaches. Immunotargets Ther 10:63–85. https://doi.org/10.2147/itt.s280706CrossRefPubMedPubMedCentral

Hoste L, researchers M-C, Soriano-Arandes A, et al (2022) Severe acute respiratory syndrome coronavirus 2 vaccination in children with a history of multisystem inflammatory syndrome in children: an international survey. J Pediatrics 248:114–118. https://doi.org/10.1016/j.jpeds.2022.05.028CrossRef

Howe HL, Amarin JZ, Hayek H et al (2022) Safety and Immunogenicity of SARS-CoV-2 vaccination in children with a history of MIS-C. Open Forum Infect Dis. https://doi.org/10.1093/ofid/ofac492.637CrossRefPubMedPubMedCentral

Kenney PO, Chang A, Krabill L, Hicar M (2023) Decreased clinical severity of pediatric acute COVID-19 and MIS-C and increase of incidental cases during the omicron wave in comparison to the delta wave. Viruses. https://doi.org/10.3390/v15010180CrossRefPubMedPubMedCentral

Khanmohammadi S, Rezaei N, Khazaei M, Shirkani A (2021) A case of autosomal recessive interferon alpha/beta receptor alpha chain (IFNAR1) deficiency with severe COVID-19. J Clin Immunol 42:19–24. https://doi.org/10.1007/s10875-021-01166-5CrossRefPubMedPubMedCentral

Klein N, Stockwell M, Demarco M et al (2022) Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19–associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 Years—VISION Network, 10 States, April 2021–January 2022. MMWR Morbidity Mortality Weekly Report. https://doi.org/10.1585/mmwr.mm7109e3CrossRefPubMedPubMedCentral

Kumrah R, Vignesh P, Rawat A, Singh S (2020) Immunogenetics of Kawasaki disease. Clin Rev Allerg Immu 59:122–139. https://doi.org/10.1007/s12016-020-08783-9CrossRef

Levy N, Koppel JH, Kaplan O et al (2022) Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. https://doi.org/10.1001/jama.2022.8025CrossRefPubMedPubMedCentral

Lim L, Lim SJ, Loy JS, Ng DC (2021) Multisystem inflammatory syndrome in children (MIS-C) occurring in temporal proximity between siblings. Bmj Case Reports 14:246066. https://doi.org/10.1136/bcr-2021-246066CrossRef

Lo MS (2020) A framework for understanding Kawasaki disease pathogenesis. Clin Immunol 214:108385. https://doi.org/10.1016/j.clim.2020.108385CrossRefPubMed

Loske J, Röhmel J, Lukassen S et al (2021) Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 40:319–324. https://doi.org/10.1038/s41587-021-01037-9CrossRefPubMed

Luo H, Liu D, Liu W et al (2021) Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. Eur J Hum Genet 29:1312–1315. https://doi.org/10.1038/s41431-021-00886-xCrossRefPubMedPubMedCentral

Malle L, Bastard P, Martín-Nalda A et al (2021) Atypical inflammatory syndrome triggered by SARS-CoV-2 in infants with down syndrome. J Clin Immunol 41:1457–1462. https://doi.org/10.1007/s10875-021-01078-4CrossRefPubMedPubMedCentral

Marks KJ, Whitaker M, Anglin O et al (2022) Hospitalizations of children and adolescents with laboratory-confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022. Morbidity Mortal Wkly Rep 71:271–278. https://doi.org/10.1585/mmwr.mm7107e4CrossRef

Mathew D, Giles JR, Baxter AE et al (2020) Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369:eabc8511. https://doi.org/10.1126/science.abc8511CrossRefPubMedPubMedCentral

Matuozzo D, Talouarn E, Marchal A et al (2022) Rare predicted loss-of-function variants of type I IFN immunity genes are associated with critical COVID-19. medRxiv. https://doi.org/10.1101/2022.10.22.22281221CrossRefPubMedPubMedCentral

McGonagle D, Ramanan AV, Bridgewood C (2021) Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol 17:145–157. https://doi.org/10.1038/s41584-020-00571-1CrossRefPubMedPubMedCentral

Meisel C, Akbil B, Meyer TW et al (2021) Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J Clin Invest. https://doi.org/10.1172/jci150867CrossRefPubMedPubMedCentral

Middelburg JG, Crijnen TEM, D’Antiga L et al (2021) Association of ethnicity with multisystem inflammatory syndrome in children related to SARS-CoV-2 infection: an international case-referent study. Frontiers Pediatrics 9:707650. https://doi.org/10.3389/fped.2021.707650CrossRef

Miller AD, Yousaf AR, Bornstein E et al (2022) multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 delta and omicron variant circulation—United States, July 2021—January 2022. Clin Infect Dis Official Publ Infect Dis Soc Am 75:ciac471. https://doi.org/10.1093/cid/ciac471CrossRef

Minoia F, Lucioni F, Heshin-Bekenstein M et al (2022) Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey. Frontiers Pediatrics 10:1030083. https://doi.org/10.3389/fped.2022.1030083CrossRef

Moga E, Lynton-Pons E, Domingo P (2022) The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Front Immunol 13:904686. https://doi.org/10.3389/fimmu.2022.904686CrossRefPubMedPubMedCentral

Moreews M, Gouge KL, Khaldi-Plassart S et al (2021) Polyclonal expansion of TCR Vb 21 3+ CD4+ and CD8+ T cells is a hallmark of multisystem inflammatory syndrome in children. Sci Immunol 6:1516. https://doi.org/10.1126/sciimmunol.abh1516CrossRef

Namkoong H, Edahiro R, Takano T et al (2022) DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature 609:754–760. https://doi.org/10.1038/s41586-022-05163-5CrossRefPubMedPubMedCentral

Onouchi Y, Ozaki K, Burns JC et al (2012) A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44:517–521. https://doi.org/10.1038/ng.2220CrossRefPubMed

Onouchi Y, Fukazawa R, Yamamura K et al (2016) Variations in ORAI1 gene associated with Kawasaki disease. Plos One 11:e0145486. https://doi.org/10.1371/journal.pone.0145486CrossRefPubMedPubMedCentral

Ouldali N, Bagheri H, Salvo F et al (2022) Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Regional Heal - Europe 17:100393. https://doi.org/10.1016/j.lanepe.2022.100393CrossRef

Palmer S, Cunniffe N, Donnelly R (2021) COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production. J Roy Soc Interface 18:20200982. https://doi.org/10.1098/rsif.2020.0982CrossRef

Pellegrino R, Chiappini E, Licari A et al (2022) Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr 181:3995–4009CrossRefPubMedPubMedCentral

Pierce CA, Sy S, Galen B et al (2021) Natural mucosal barriers and COVID-19 in children. Jci Insight 6:148694. https://doi.org/10.1172/jci.insight.148694CrossRefPubMed

Piret J, Boivin G (2022) Viral interference between respiratory viruses—volume 28, number 2—February 2022 - emerging infectious diseases journal—CDC. Emerg Infect Dis 28:273–281. https://doi.org/10.3201/eid2802.211727CrossRefPubMedPubMedCentral

Porritt RA, Binek A, Paschold L et al (2021) The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J Clin Invest. https://doi.org/10.1172/jci151520CrossRefPubMedPubMedCentral

Porritt RA, Paschold L, Rivas MN et al (2021) HLA class I-associated expansion of TRBV11–2 T cells in multisystem inflammatory syndrome in children. J Clin Invest. https://doi.org/10.1172/jci146614CrossRefPubMedPubMedCentral

Ramaswamy A, Brodsky NN, Sumida TS et al (2021) Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 54:1083-1095.e7. https://doi.org/10.1016/j.immuni.2021.04.003CrossRefPubMedPubMedCentral

Rivas MN, Porritt RA, Cheng MH et al (2021) COVID-19–associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome—the superantigen hypothesis. J Allergy Clin Immun 147:57–59. https://doi.org/10.1016/j.jaci.2020.10.008CrossRef

Rivas MN, Porritt RA, Cheng MH et al (2022) Multisystem inflammatory syndrome in children and Long COVID: The SARS-CoV-2 viral superantigen hypothesis. Front Immunol 13:941009CrossRef

Rodriguez-Smith JJ, Verweyen EL, Clay GM et al (2021) Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. Lancet Rheumatology 3:e574–e584. https://doi.org/10.1016/s2665-9913(21)00139-9CrossRefPubMed

Ronit A, Jørgensen SE, Roed C et al (2021) Host genetics and antiviral immune responses in adult patients with multisystem inflammatory syndrome. Front Immunol 12:718744. https://doi.org/10.3389/fimmu.2021.718744CrossRefPubMedPubMedCentral

Rosene KA, Copass MK, Kastner LS et al (1982) Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 96:865. https://doi.org/10.7326/0003-4819-96-6-865CrossRefPubMed

Sacco K, Castagnoli R, Vakkilainen S et al (2022) Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat Med 28:1050–1062. https://doi.org/10.1038/s41591-022-01724-3CrossRefPubMedPubMedCentral

Santos MO, Gonçalves LC, Silva PAN et al (2021) Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes. J Pediat. https://doi.org/10.1016/j.jped.2021.08.006CrossRefPubMed

Schimke LF, Marques AHC, Baiocchi GC et al (2022) Severe COVID-19 shares a common neutrophil activation signature with other acute inflammatory states. Cells 11:847. https://doi.org/10.3390/cells11050847CrossRefPubMedPubMedCentral

Schmidt A, Peters S, Knaus A et al (2021) TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. Npj Genom Med 6:55. https://doi.org/10.1038/s41525-021-00220-wCrossRefPubMedPubMedCentral

Schulert GS, Blum SA, Cron RQ (2021) Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. Curr Opin Pediatr 33:549–555. https://doi.org/10.1097/mop.0000000000001061CrossRefPubMedPubMedCentral

Sefik E, Qu R, Junqueira C et al (2022) Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606:585–593. https://doi.org/10.1038/s41586-022-04802-1CrossRefPubMedPubMedCentral

Shane AL, Sato AI, Kao C et al (2020) A pediatric infectious disease perspective of SARS-CoV-2 and COVID-19 in Children. J Pediatric Infect Dis Soc. https://doi.org/10.1093/jpids/piaa099CrossRefPubMedPubMedCentral

Shaw ER, Rosen LB, Cheng A et al (2021) Temporal dynamics of anti-type 1 interferon autoantibodies in patients with coronavirus disease 2019. Clin Infect Dis Official Publ Infect Dis Soc Am 75:e1192–e1194. https://doi.org/10.1093/cid/ciab1002CrossRef

Shi D, Whitaker M, Marks KJ et al (2022) Hospitalizations of children aged 5–11 years with laboratory-confirmed COVID-19—COVID-NET, 14 States, March 2020–February 2022. Morbidity Mortal Wkly Rep 71:574–581. https://doi.org/10.1585/mmwr.mm7116e1CrossRef

Shingleton J, Williams H, Oligbu G et al (2022) The changing epidemiology of PIMS-TS across COVID-19 waves: prospective national surveillance, January 2021 to July 2022, England. J Infection 85:702–769. https://doi.org/10.1016/j.jinf.2022.10.017CrossRef

Son K, Jamil R, Chowdhury A et al (2022) Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. European Respir J 61:2200970. https://doi.org/10.1183/13993003.00970-2022CrossRef

Sorg A-L, Hufnagel M, Doenhardt M et al (2022a) Risk for severe outcomes of COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany. Eur J Pediatr 181:3635–3643. https://doi.org/10.1007/s00431-022-04587-5CrossRefPubMedPubMedCentral

Sorg AL, Schönfeld V, Siedler A et al (2022) SARS-CoV-2 variants and the risk of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 among children in Germany. Infection. https://doi.org/10.1007/s15010-022-01908-6CrossRefPubMedPubMedCentral

Soriano JB, Murthy S, Marshall JC et al (2022) A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22:e102–e107. https://doi.org/10.1016/s1473-3099(21)00703-9CrossRefPubMed

Stierman B, Abrams JY, Godfred-Cato SE et al (2021) Racial and ethnic disparities in multisystem inflammatory syndrome in children in the United States, March 2020 to February 2021. Pediatric Infect Dis J 40:e400–e406. https://doi.org/10.1097/inf.0000000000003294CrossRef

Su Y, Yuan D, Chen DG et al (2022) Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185:881-895.e20. https://doi.org/10.1016/j.cell.2022.01.014CrossRefPubMedPubMedCentral

Swadling L, Diniz MO, Schmidt NM et al (2021) Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601:110–117. https://doi.org/10.1038/s41586-021-04186-8CrossRefPubMedPubMedCentral

Szekanecz Z, Balog A, Constantin T et al (2022) COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. Expert Rev Mol Med 24:e13. https://doi.org/10.1017/erm.2022.10CrossRefPubMedPubMedCentral

Tan SHX, Cook AR, Heng D et al (2022) Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age. New Engl J Med 387:525–532. https://doi.org/10.1056/nejmoa2203209CrossRefPubMed

Tang J, Novak T, Hecker J et al (2022) Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun 13:2979. https://doi.org/10.1038/s41467-022-30649-1CrossRefPubMedPubMedCentral

Vagrecha A, Zhang M, Acharya S et al (2022) Hemophagocytic lymphohistiocytosis gene variants in multisystem inflammatory syndrome in children. Biology 11:417. https://doi.org/10.3390/biology11030417CrossRefPubMedPubMedCentral

van der Wijst MGP, Vazquez SE, Hartoularos GC et al (2021) Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med 13:eabh2624. https://doi.org/10.1126/scitranslmed.abh2624CrossRefPubMedPubMedCentral

Wang F, Nie J, Wang H et al (2020) Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 221:150. https://doi.org/10.1093/infdis/jiaa150CrossRef

Wang EY, Mao T, Klein J et al (2021) Diverse functional autoantibodies in patients with COVID-19. Nature 595:283–288. https://doi.org/10.1038/s41586-021-03631-yCrossRefPubMed

Wang L, Berger NA, Kaelber DC et al (2022) Incidence rates and clinical outcomes of SARS-CoV-2 infection with the omicron and delta variants in children younger than 5 Years in the US. Jama Pediatr 176:811–813. https://doi.org/10.1001/jamapediatrics.2022.0945CrossRefPubMedPubMedCentral

Whittaker E, Bamford A, Kenny J et al (2020) Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324:259–269. https://doi.org/10.1001/jama.2020.10369CrossRefPubMedPubMedCentral

Whittaker R, Greve-Isdahl M, Bøås H, et al (2022) COVID-19 Hospitalization Among Children <18 Years by Variant Wave in Norway. Pediatrics 150:. https://doi.org/10.1542/peds.2022-057564

Xie X, Shi X, Liu M (2018) The roles of genetic factors in kawasaki disease: a systematic review and meta-analysis of genetic association studies. Pediatr Cardiol 39:207–225. https://doi.org/10.1007/s00246-017-1760-0CrossRefPubMed

Xu Y, Li X, Zhu B et al (2020) Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 26:502–505. https://doi.org/10.1038/s41591-020-0817-4CrossRefPubMedPubMedCentral

Yang M (2020) Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. Ssrn Electron J. https://doi.org/10.2139/ssrn.3527420CrossRef

Yonker LM, Gilboa T, Ogata AF et al (2021) Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. https://doi.org/10.1172/jci149633CrossRefPubMedPubMedCentral

Yoshida M, Worlock KB, Huang N et al (2021) Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature 602:321–327. https://doi.org/10.1038/s41586-021-04345-xCrossRefPubMedPubMedCentral

Yousaf AR, Cortese MM, Taylor AW et al (2022) Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Heal 6:303–312. https://doi.org/10.1016/s2352-4642(22)00028-1CrossRef

Zambrano LD, Newhams MM, Olson SM et al (2022) Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States july–december 2021. Morbidity Mortal Wkly Rep 71:52–58. https://doi.org/10.15585/mmwr.mm7102e1CrossRef

Zhang Q, Bastard P, Bolze A et al (2020) Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med 1:14–20. https://doi.org/10.1016/j.medj.2020.12.001CrossRefPubMed

Zhang Q, Bastard P, Effort CHG et al (2022a) Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603:587–598. https://doi.org/10.1038/s41586-022-04447-0CrossRefPubMedPubMedCentral

Zhang Q, Matuozzo D, Pen JL et al (2022) Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med 219:e20220131. https://doi.org/10.1084/jem.20220131CrossRefPubMedPubMedCentral

Zhang H-P, Sun Y-L, Wang Y-F et al (2023) Recent developments in the immunopathology of COVID-19. Allergy 78:369–388. https://doi.org/10.1111/all.15593CrossRefPubMed

Zheng X, Chen W, Gong F et al (2021) The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: a review. Front Immunol 12:711939. https://doi.org/10.3389/fimmu.2021.711939CrossRefPubMedPubMedCentral

Title: Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID
Authors: Tamás Constantin
Tamás Pék
Zsuzsanna Horváth
Diána Garan
Attila J. Szabó
Publication date: 17-07-2023
Publisher: Springer International Publishing
Keywords: Long-COVID Syndrome
SARS-CoV-2
COVID-19
Kawasaki Disease
Kawasaki Disease
Kawasaki Disease
Published in: Inflammopharmacology / Issue 5/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01272-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2023

Anti-inflammatory, cardioprotective effect of gypenoside against isoproterenol-induced cardiac remodeling in rats via alteration of inflammation and gut microbiota

Meta-analysis of the anti-oxidative and anti-inflammatory effects of hypoglycaemic plant-derived medicines

The effects of pomegranate consumption on inflammatory and oxidative stress biomarkers in adults: a systematic review and meta-analysis

Phytochemical analysis and antibacterial/antifungal activity of the essential oil of Phlomis olivieri Benth in Iran

Vitamin K2 protects against aluminium chloride-mediated neurodegeneration

The effect of magnesium sulfate on gene expression and serum level of inflammatory cytokines in coronary artery disease patients